科代诊断美股招股说明书(2025-10-20版)

We have entered into an Equity Distribution Agreement with Maxim Group LLC (“Maxim”), dated October 20, 2025, relating to thesale of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms ofthe Equity Distribution Agreement, under this prospectus supplement and the accompanying prospectus, we may offer and sell up to$4,086,645 of shares of our common stock, $0.001 par value per share (the “Common Stock”), from time to time through Maximacting as agent. Sales of our Common Stock, if any, under this prospectus supplement and accompanying prospectus may be made in sales deemed tobe “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act.Maxim is not required to sell any specific dollar amount of shares but will use commercially reasonable efforts to sell on our behalf allof the shares of Common Stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreedterms between Maxim and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. Weprovide more information about how the shares of Common Stock will be sold in the section entitled “Plan of Distribution.” Maxim will be entitled to compensation at a fixed commission rate of 3% of the gross sales price per share sold. In connection with thesale of our Common Stock on our behalf, Maxim will be deemed to be an “underwriter” within the meaning of the Securities Act andthe compensation of Maxim will be deemed to be underwriting commissions or discounts. We have also agreed to provideindemnification and contribution to Maxim with respect to certain liabilities, including liabilities under the Securities Act. Our Common Stock is listed on The Nasdaq Capital Market under the symbol “CODX.” The last reported sale price of our CommonStock on The Nasdaq Capital Market on October 17, 2025 was $0.3242 per share. We are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement ofwhich this prospectus supplement and the Prospectus form a part. The aggregate market value of our Common Stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is approximately $28,939,245, which was calculated based onapproximately 45,302,513 shares of our outstanding Common Stock held by non-affiliates on October 20, 2025 at a price of $0.6388per share, the closing price of our Common Stock on September 16, 2025. During the 12 calendar months prior to, and including, thedate of this prospectus supplement, we have sold approximately $5,559,770 of securities pursuant to General Instruction I.B.6 of FormS-3. As a result, we are currently eligible to offer and sell up to an aggregate of approximately $4,086,645 of our securities pursuant toGeneral Instruction I.B.6 of Form S-3. Investing in the offered securities involves a high degree of risk. See “Risk Factors” beginning on page S-4 of this prospectussupplement and page 6 of the accompanying prospectus for a discussion of information that you should consider beforeinvestingin our securities and in the documents incorporated by reference in this prospectus supplement and theaccompanying prospectus that we file with the Securities and Exchange Commission. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Anyrepresentation to the contrary is a criminal offense. Sole Sales Agent Maxim Group LLC The date of this prospectus supplement is October 20, 2025 TABLE OF CONTENTS PagePROSPECTUS SUPPLEMENTABOUT THIS PROSPECTUS SUPPLEMENTS-iiCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSS-iiiSUMMARY OF THE PROSPECTUS SUPPLEMENTS-1THE OFFERINGS-3RISK FACTORSS-4USE OF PROCEEDSS-6DESCRIPTION OF CAPITAL STOCK AND SECURITIES THAT WE ARE OFFERINGS-7PLAN OF DISTRIBUTIONS-8LEGAL MATTERSS-9EXPERTSS-9WHERE YOU CAN FIND ADDITIONAL INFORMATIONS-9INCORPORATION OF DOCUMENTS BY REFERENCES-9 TABLE OF CONTENTS PageABOUT THIS PROSPECTUS1CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS2PROSPECTUS SUMMARY3RISK FACTORS6USE OF PROCEEDS7DESCRIPTION OF CAPITAL STOCK8DESCRIPTION OF DEBT SECURITIES15DESCRIPTION OF WARRANTS21DESCRIPTION OF RIGHTS22DESCRIPTION OF UNITS23FORMS OF SECURITIES24PLAN OF DISTRIBUTION25LEGAL MATTERS28EXPERTS28WHERE YOU CAN FIND MORE INFORMATION28INCORPORATION BY REFERENCE28 You should rely only on the information we have provided or incorporated by reference in this prospectus supplement and theaccompanying prospectus. We have not authorized anyone to provide you with information different from that contained orincorporated by reference in this prospectus supplement or the accompanying prospectus. This prospectus supplement and any later prospectus suppl